$5.03
Vir Biotechnology
Performance
Dividends
1W
1M
YTD
1Y
3Y
8/36
Growth
Score
9/36
Dividend
Score
Valuation
PE Ratio
-1.2
PS Ratio
35.43
RSI
-
PEG Ratio
-0.17
PRG Ratio
0
0
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
Rule
of 40
-5.75%
Gross Margin
68.7%
3
Current Ratio
6.79
Return on Assets
-44.17%
0
Return on Equity
-47.46%
0
Return on inv. Capital
-51.19%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 74.20M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -521.96M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 73.36M
2018
2019
2020
2021
2022
2023
2024
6
Events
VIR
Vir Biotechnology
in 265 days
after market close
Earnings per Share is expected with - and revenue with - .
VIR
Vir Biotechnology
in 195 days
after market close
Earnings per Share is expected with - and revenue with - .
VIR
Vir Biotechnology
in 77 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
11.10.2019
MaketCap
695.34M
Country
US
CEO
Marianne De Backer
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Updated 04.08.2025